Skip to main content
Erschienen in: Journal of Diabetes & Metabolic Disorders 1/2022

10.03.2022 | Case report

Familial hypercholesterolemia in an Iranian family due to a mutation in the APOE gene (first case report)

verfasst von: Shahab Noorian, Rezvan Razmandeh, Roshanak Jazayeri

Erschienen in: Journal of Diabetes & Metabolic Disorders | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Familial Hypercholesterolemia is an autosomal, dominant genetic disorder associated with premature cardiovascular disease (CVD). Mutations in the LDLR, APOB, and PCSK9 genes cause the FH phenotype, but in 20% of FH patients, mutations in other genes cause FH. In this regard, we investigated the genetic basis of an Autosomal Dominant Hypercholesterolemia (ADH) phenotype in an Iranian family via next-generation exome sequencing with a panel of hyperlipidemia. We report the first case of FH in an Iranian family due to a mutation in the APOE gene. A 10-year-old female was referred to our genetic clinic with a family history of hypercholesterolemia and high cholesterol level at the age of 3. Evaluation of the lipid profile showed the off total cholesterol of 338 mg/dl, low-density lipoprotein cholesterol (LDL-C of 247 mg/dl(. We identified a mutation in the APOE gene, c.500_502del /p. Leu167del confirmed co-segregation in three individuals of the family from three generations. This in-frame mutation identified here, the first report in Iran, confirms previous reports that ADH can be caused by mutations within the APOE gene and strongly introduces it as the 4th gene that must be checked in the genetic investigating of FH.
Literatur
1.
Zurück zum Zitat Wonderling D, Umans-Eckenhausen MA, Marks D, Defesche JC, Kastelein JJ, Thorogood M, editors. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Seminars in vascular medicine; 2004: Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Wonderling D, Umans-Eckenhausen MA, Marks D, Defesche JC, Kastelein JJ, Thorogood M, editors. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Seminars in vascular medicine; 2004: Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
2.
Zurück zum Zitat Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004;160(5):421–9.CrossRef Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004;160(5):421–9.CrossRef
3.
Zurück zum Zitat van Aalst-Cohen ES, Jansen AC, Tanck MW, Defesche JC, Trip MD, Lansberg PJ, et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J. 2006;27(18):2240–6.CrossRef van Aalst-Cohen ES, Jansen AC, Tanck MW, Defesche JC, Trip MD, Lansberg PJ, et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J. 2006;27(18):2240–6.CrossRef
4.
Zurück zum Zitat Movahedian A, Ghannadi A, Vashirnia M. Hypocholesterolemic effects of purslane extract on serum lipids in rabbits fed with high cholesterol levels. Int J Pharmacol. 2007;3(3):285–9.CrossRef Movahedian A, Ghannadi A, Vashirnia M. Hypocholesterolemic effects of purslane extract on serum lipids in rabbits fed with high cholesterol levels. Int J Pharmacol. 2007;3(3):285–9.CrossRef
5.
Zurück zum Zitat Awan Z, Choi HY, Stitziel N, Ruel I, Bamimore MA, Husa R, et al. APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis. 2013;231(2):218–22.CrossRef Awan Z, Choi HY, Stitziel N, Ruel I, Bamimore MA, Husa R, et al. APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis. 2013;231(2):218–22.CrossRef
6.
Zurück zum Zitat Marduel M, Ouguerram K, Serre V, Bonnefont-Rousselot D, Marques-Pinheiro A, Erik Berge K, et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum Mutat. 2013;34(1):83–7. Marduel M, Ouguerram K, Serre V, Bonnefont-Rousselot D, Marques-Pinheiro A, Erik Berge K, et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum Mutat. 2013;34(1):83–7.
7.
Zurück zum Zitat Okorodudu DE, Crowley MJ, Sebastian S, Rowell JV, Guyton JR. Inherited lipemic splenomegaly and the spectrum of apolipoprotein E p.Leu167del mutation phenotypic variation. J Clin Lipidol. 2013;7(6):566–72.CrossRef Okorodudu DE, Crowley MJ, Sebastian S, Rowell JV, Guyton JR. Inherited lipemic splenomegaly and the spectrum of apolipoprotein E p.Leu167del mutation phenotypic variation. J Clin Lipidol. 2013;7(6):566–72.CrossRef
8.
Zurück zum Zitat Subramani KS, Kolhari VB, Manjunath CN, Bhairappa S. Familial hypercholesterolaemia presenting with coronary artery disease in a young patient. BMJ Case Rep 2013;2013:bcr2013008718. Subramani KS, Kolhari VB, Manjunath CN, Bhairappa S. Familial hypercholesterolaemia presenting with coronary artery disease in a young patient. BMJ Case Rep 2013;2013:bcr2013008718.
9.
Zurück zum Zitat Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci. 2006;7(11):850–9.CrossRef Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci. 2006;7(11):850–9.CrossRef
10.
Zurück zum Zitat Cenarro A, Etxebarria A, de Castro-Oros I, Stef M, Bea AM, Palacios L, et al. The p.Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by Down-regulation of LDL receptor expression in hepatocytes. J Clin Endocrinol Metab. 2016;101(5):2113–21.CrossRef Cenarro A, Etxebarria A, de Castro-Oros I, Stef M, Bea AM, Palacios L, et al. The p.Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by Down-regulation of LDL receptor expression in hepatocytes. J Clin Endocrinol Metab. 2016;101(5):2113–21.CrossRef
11.
Zurück zum Zitat Henderson R, O'Kane M, McGilligan V, Watterson S. The genetics and screening of familial hypercholesterolaemia. J Biomed Sci. 2016;23:39.CrossRef Henderson R, O'Kane M, McGilligan V, Watterson S. The genetics and screening of familial hypercholesterolaemia. J Biomed Sci. 2016;23:39.CrossRef
13.
Zurück zum Zitat Nguyen TT, Kruckeberg KE, O'Brien JF, Ji ZS, Karnes PS, Crotty TB, et al. Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)]. J Clin Endocrinol Metab. 2000;85(11):4354–8.PubMed Nguyen TT, Kruckeberg KE, O'Brien JF, Ji ZS, Karnes PS, Crotty TB, et al. Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)]. J Clin Endocrinol Metab. 2000;85(11):4354–8.PubMed
14.
Zurück zum Zitat Faivre L, Saugier-Veber P, Pais de Barros JP, Verges B, Couret B, Lorcerie B, et al. Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation. Eur J Hum Genet: EJHG. 2005;13(11):1186–91.CrossRef Faivre L, Saugier-Veber P, Pais de Barros JP, Verges B, Couret B, Lorcerie B, et al. Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation. Eur J Hum Genet: EJHG. 2005;13(11):1186–91.CrossRef
15.
Zurück zum Zitat Rahalkar AR, Wang J, Sirrs S, Dimmick J, Holmes D, Urquhart N, et al. An unusual case of severe hypertriglyceridemia and splenomegaly. Clin Chem 2008;54(3):606-10; discussion 10-1. Rahalkar AR, Wang J, Sirrs S, Dimmick J, Holmes D, Urquhart N, et al. An unusual case of severe hypertriglyceridemia and splenomegaly. Clin Chem 2008;54(3):606-10; discussion 10-1.
16.
Zurück zum Zitat Mohd Nor NS, Al-Khateeb AM, Chua Y-A, Mohd Kasim NA, Mohd NH. Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review. BMC Pediatr. 2019;19(1):106.CrossRef Mohd Nor NS, Al-Khateeb AM, Chua Y-A, Mohd Kasim NA, Mohd NH. Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review. BMC Pediatr. 2019;19(1):106.CrossRef
17.
Zurück zum Zitat Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425–37.CrossRef Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425–37.CrossRef
18.
Zurück zum Zitat Moorjani S, Roy M, Gagne C, Davignon J, Brun D, Toussaint M, et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis (Dallas, Tex). 1989;9(2):211–6. Moorjani S, Roy M, Gagne C, Davignon J, Brun D, Toussaint M, et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis (Dallas, Tex). 1989;9(2):211–6.
19.
Zurück zum Zitat Wintjens R, Bozon D, Belabbas K, MBou F, Girardet JP, Tounian P, et al. Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France. J Lipid Res. 2016;57(3):482–91.CrossRef Wintjens R, Bozon D, Belabbas K, MBou F, Girardet JP, Tounian P, et al. Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France. J Lipid Res. 2016;57(3):482–91.CrossRef
20.
Zurück zum Zitat Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (Clinical research ed). 2008;337:a2423.CrossRef Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (Clinical research ed). 2008;337:a2423.CrossRef
21.
Zurück zum Zitat Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial h. BMJ (Clinical research ed). 2002;324(7349):1303.CrossRef Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial h. BMJ (Clinical research ed). 2002;324(7349):1303.CrossRef
Metadaten
Titel
Familial hypercholesterolemia in an Iranian family due to a mutation in the APOE gene (first case report)
verfasst von
Shahab Noorian
Rezvan Razmandeh
Roshanak Jazayeri
Publikationsdatum
10.03.2022
Verlag
Springer International Publishing
Erschienen in
Journal of Diabetes & Metabolic Disorders / Ausgabe 1/2022
Elektronische ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-022-01007-1

Weitere Artikel der Ausgabe 1/2022

Journal of Diabetes & Metabolic Disorders 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.